Clinical Trials Logo

Prostatic Hyperplasia clinical trials

View clinical trials related to Prostatic Hyperplasia.

Filter by:

NCT ID: NCT05574244 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction

PARTURP
Start date: September 29, 2022
Phase: N/A
Study type: Interventional

It has been demonstrated that sexual activity was common in the majority of men over 50 years old and was an important component of overall quality of life (QoL). Ejaculatory dysfunction (EjD) is the most common side effect of surgical treatment of benign prostatic obstruction (BPO). It has been considered for decades to be an inevitable consequence of restoring micturition comfort. EjD can have a substantial deleterious effect on the QoL of men with previously maintained regular sexual activity, inducing decreased orgasmic intensity and increased levels of anxiety and depression. A better understanding of the physiology of ejaculation has enabled the emergence of modified surgical techniques that aim to preserve antegrade ejaculation. Our hypothesis is that conservation of ejaculation can be achieved by modified surgical procedures without compromising functional outcomes.

NCT ID: NCT05567666 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)

SUMMIT
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.

NCT ID: NCT05551221 Recruiting - Clinical trials for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

NQTIPS
Start date: July 18, 2022
Phase: Phase 4
Study type: Interventional

Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study. Interventions: Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.

NCT ID: NCT05543200 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

BPH Global Registry

Start date: March 13, 2023
Phase:
Study type: Observational [Patient Registry]

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

NCT ID: NCT05531344 Completed - Clinical trials for Benign Prostatic Hyperplasia

Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia

Start date: August 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, randomized, open-label, parallel-group, medication-control, superiority, multicenter clinical study trial. This study is studying the effects and safety in treating patients from nine different centers with Benign prostatic hyperplasia, employing Composite Steep-pulse(High-frequency irreversible electroporation) Treatment Apparatus. This device could cause cell irreversible electroporation, which leading necrosis of hyperplasia tissue cells. It also has the ability to prevent nerve,vessel, urethral and capsule unnecessary injury beside the ablation area. Composite Steep-pulse Treatment Apparatus will be used in patients who pass inclusion/exclusion criteria. Safety, quality of life, and urodynamic data analysis of each patient will be evaluated in each study patients.

NCT ID: NCT05531240 Recruiting - Clinical trials for Prostate Hyperplasia

Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE)

Start date: October 2022
Phase: N/A
Study type: Interventional

This study focuses on the treatment of benign prostatic hyperplasia which causes lower urinary tract symptoms. The purpose of the research project is to evaluate PAE in terms of both medical and health economic outcomes. To evaluate whether there are any differences in effect (IPSS), complications, costs and perceived quality of life compared with TUR-P.

NCT ID: NCT05506735 Completed - Prostate Cancer Clinical Trials

The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family History

PSA
Start date: May 1, 2022
Phase:
Study type: Observational

The seven sweeps is a recommended act performed by men after urinating in order to be confident that no urine is left in the urethra, and its not compulsory to perform. It is performed by the following way: after urinating, the anus is first purified if it has become impure; then, the middle finger of the left hand is slid three times from the anus up to the scrotum; then, the thumb is placed on the penis and the forefinger is placed under the penis, and the thumb and forefinger are pulled three times along the penis up to the point of circumcision; finally, the end of the penis is pressed three times.

NCT ID: NCT05494944 Completed - Clinical trials for Benign Prostatic Hyperplasia

Low Power ThULEP for Prostate Size More Than 80 gm

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

Feasibility and Efficacy of lower power thulium enucleation of prostate more than 80 grams

NCT ID: NCT05494567 Active, not recruiting - Overactive Bladder Clinical Trials

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Start date: November 8, 2021
Phase: Phase 4
Study type: Interventional

The investigators will compare the efficacy and safety of tadalafil/solifenacin combination therapy versus tamsulosin/solifenacin combination therapy for the treatment of BPH/OAB in a randomized controlled trial (RCT).

NCT ID: NCT05460312 Not yet recruiting - Inflammation Clinical Trials

Protein Kinase A in Prostate Cancer Tissue.

Start date: March 1, 2023
Phase:
Study type: Observational

Prostate cancer is the most common malignancy in men. documented risk factors of prostate cancer are age, ethnicity, various genomic mutations and family history of prostate cancer. The cellular mechanisms of malignant transformation are numerous and not completely understood. A possible mechanism is induction of an inflammation resulting in cellular atypia and pre-malignant changes in the affected tissue by inducing a pro-inflammatory response or changes in extra cellular matrix. Protein Kinase A (PKA) is a key stone enzyme in various intra-cellular processes. Various infections' inflammations and malignancies were proved to impact PKA activity. The research hypothesis is that prostate cancer tissue will show a unique profile of PKA activity, regulation and intracellular distribution.